| Clinical data | |
|---|---|
| Other names | LY-03020; LPM787000048; LPM-787000048 |
| Routes of administration | Oral[1] |
| Drug class | Serotonin 5-HT2C receptor agonist |
| ATC code |
|
LY03020 is a dual serotonin 5-HT2C receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzheimer's disease.[1][2][3] It is taken orally as a controlled-release formulation.[1] The drug is under development by Luye Pharma Group.[1][2][3] As of February 2026, it is in phase 1 clinical trials for both indications.[1][2][3] The chemical structure of LY03020 does not yet appear to have been disclosed.[1]
See also
References
- "LY 03020". AdisInsight. 17 February 2026. Retrieved 27 March 2026.
- "Delving into the Latest Updates on LPM787000048 with Synapse". Synapse. 9 February 2026. Retrieved 27 March 2026.
- Sami T (27 March 2026). "Luye advances dual agonist for schizophrenia, Alzheimer's". BioWorld. Retrieved 27 March 2026.